Document Classification

Section Type: RESULTS

Text: The most frequent grade 3 or higher regorafenib-related adverse events were hand-foot skin reaction (22 [16 %] of 136 patients in the regorafenib group vs none in the placebo group), hypertension (15 [11 %] vs two [3 %] of 68 patients in the placebo group), hyperbilirubinaemia (nine [7 %] vs one [1 %]), hypophosphataemia (nine [7 %] vs none), alanine aminotransferase concentration increases (nine [7 %] vs none), aspartate aminotransferase concentration increases (eight [6 %] vs none), lipase concentration increases (six [4 %] vs one [1 %]), and maculopapular rash (six [4 %] vs none).